The Src family kinase inhibitor drug Dasatinib and glucocorticoids display synergistic activity against tongue squamous cell carcinoma and reduce MET kinase activity
Hmedat ANA. et al, (2025), Cell Communication and Signaling, 23
Drug Combinations Targeting FAK and MEK Overcomes Tumor Heterogeneity in Glioblastoma
Furqan M. et al, (2025), Pharmaceutics, 17, 549 - 549
A comprehensive pharmacological survey across heterogeneous patient-derived GBM stem cell models
Elliott RJR. et al, (2024)
A High-Throughput Drug Repurposing Strategy to Treat TBX2 and/or TBX3 Dependent Cancers.
Bleloch JS. et al, (2024), Cancer Med, 13
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors.
Kent D. et al, (2024), Hepatology
Improving the representativeness of UK's national COVID-19 Infection Survey through spatio-temporal regression and post-stratification.
Pouwels KB. et al, (2024), Nat Commun, 15
Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
Baugh R. et al, (2024), J Immunother Cancer, 12
Optimized protocol for CRISPR knockout of human iPSC-derived macrophages.
Navarro-Guerrero E. et al, (2024), STAR Protoc, 5
Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study.
Bešević J. et al, (2023), J Epidemiol Community Health, 78, 105 - 108
Selective ROCK Inhibitor Enhances Blood Flow Recovery after Hindlimb Ischemia.
Fayed HS. et al, (2023), Int J Mol Sci, 24
Chemogenomic library design strategies for precision oncology, applied to phenotypic profiling of glioblastoma patient cells.
Athanasiadis P. et al, (2023), iScience, 26
COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK.
Buckell J. et al, (2023), Sci Rep, 13
Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK.
Wei J. et al, (2023), Nat Commun, 14
Data from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)
Data from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)
Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models
Rodriguez-Berriguete G. et al, (2023)